[Translation] A single-center, randomized, open-label, two-dose, two-period, two-sequence, crossover bioequivalence study of dapagliflozin tablets (10 mg) administered orally on an empty stomach in healthy Chinese participants
主要目的:研究空腹单次给药条件下,青岛百洋制药有限公司生产的达格列净片(受试制剂,规格:10mg)和AstraZeneca Pharmaceuticals LP生产的达格列净片(参比制剂,安达唐,规格:10mg)在中国健康参与者体内的生物等效性。次要目的:评价中国健康参与者单次口服达格列净片受试制剂(规格:10mg)和参比制剂(安达唐,规格:10mg)的安全性。
[Translation] Primary objective: To study the bioequivalence of dapagliflozin tablets (test formulation, strength: 10 mg) produced by Qingdao Baiyang Pharmaceutical Co., Ltd. and dapagliflozin tablets (reference formulation, Andatang, strength: 10 mg) produced by AstraZeneca Pharmaceuticals LP in healthy Chinese participants under the condition of single fasting administration. Secondary objective: To evaluate the safety of single oral administration of dapagliflozin tablets (test formulation, strength: 10 mg) and reference formulation (Andatang, strength: 10 mg) in healthy Chinese participants.